Roche affirms sales outlook amid doubts about its future
Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.